BECN1 and diffuse large B-cell lymphoma: Our data support BECLIN-1 as a valuable prognostic biomarker to predict the response to chemotherapy and additionally indicate BECLIN-1-dependent autophagy as a target pathway to improve the response to chemotherapy and the clinical outcome in DLBCL patients.